Literature DB >> 31322550

MicroRNA-429 inhibits cancer cell proliferation and migration by targeting the AKT1 in melanoma.

Deshun Huang, Fuxi Wang, Wenzhong Wu, Cuihong Lian, Enrang Liu.   

Abstract

MicroRNAs (miRNAs; miR) have been proven to act as both oncogenes and tumor suppressors. However, the mechanism of action of miR429 in melanoma cells remains to be elusive. The present study aims to explain the functional role and mechanism of miR429 in the pathogenesis of melanoma. In our study, we have demonstrated that has-miRNA429 (miR429) is a tumor suppressor in melanoma cells. Luciferase reporter assays demonstrated that the overexpression of miR429 reduced the transcriptional activity of AKT serine/threonine kinase 1 (AKT1). Furthermore, the results showed that the mRNA and protein expression levels of AKT1 were downregulated in the melanoma cell lines when miR429 was overexpressed according to qRT-PCR and western bolt, indicating MicroRNA-429 may directly target AKT1 in melanoma. In vivo, overexpression miR-429 could obviously enhance the inhibition effect of tumor size and weight in the nude mice. Taken together, our findings suggest that novel miR429-regulated pathway may serve as new insights into melanoma oncogenesis and metastasis.

Entities:  

Keywords:  AKT1; Melanoma cells; miR429

Mesh:

Substances:

Year:  2019        PMID: 31322550     DOI: 10.3233/CBM-190289

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  10 in total

1.  Down-regulated expression of miR-582 predicts poor prognosis and facilitates melanoma progression by targeting FOXC1.

Authors:  Fang Chen; Dapeng Zhang
Journal:  Arch Dermatol Res       Date:  2021-10-10       Impact factor: 3.033

Review 2.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

3.  MicroRNA-495 serves as a diagnostic biomarker in patients with sepsis and regulates sepsis-induced inflammation and cardiac dysfunction.

Authors:  Hailei Guo; Liying Tang; Jianjun Xu; Cai Lin; Xiangwei Ling; Caijiao Lu; Zhengjun Liu
Journal:  Eur J Med Res       Date:  2019-11-26       Impact factor: 2.175

Review 4.  The miRNAs Role in Melanoma and in Its Resistance to Therapy.

Authors:  Francesca Varrone; Emilia Caputo
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

5.  MiR-429 Involves in the Pathogenesis of Colorectal Cancer via Directly Targeting LATS2.

Authors:  Xia Chen; Ai-Li Wang; Yuan-Yuan Liu; Chen-Xi Zhao; Xue Zhou; Hai-Long Liu; Mo-Bin Lin
Journal:  Oxid Med Cell Longev       Date:  2020-12-19       Impact factor: 6.543

6.  Bioinformatics Analysis to Screen Key Targets of Curcumin against Colorectal Cancer and the Correlation with Tumor-Infiltrating Immune Cells.

Authors:  Xinyue Han; Chao Yang; Cui Guo; Yimin Xu; Xiaoqiang Liu; Runnan Xie; Xiangxue Meng; Zhihong Cheng; Xiaoling Fu
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-12       Impact factor: 2.629

Review 7.  The role of miR-200 family in the regulation of hallmarks of cancer.

Authors:  Klaudia Klicka; Tomasz M Grzywa; Aleksandra Mielniczuk; Alicja Klinke; Paweł K Włodarski
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

8.  Aberrant Expression of miR-592 Is Associated with Prognosis and Progression of Renal Cell Carcinoma.

Authors:  Xianbao Lv; Jingang Shen; Zhen Guo; Lingwei Kong; Guangchun Zhou; Hao Ning
Journal:  Onco Targets Ther       Date:  2019-12-18       Impact factor: 4.147

9.  MicroRNA-663 Regulates Melanoma Progression by Inhibiting FHL3.

Authors:  Saijun Liu; Yunfeng Hu; Shi Wu; Yong He; Liehua Deng
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

10.  Circular RNA circRNA_0082835 promotes progression and lymphatic metastasis of primary melanoma by sponging microRNA miRNA-429.

Authors:  Yute Sun; Zuoqiong Hou; Binlin Luo; Chujun Li; Jinfang Liu; Jianlan Liu; Jian Tang; Gang Yao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.